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NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of
treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum
combination was found to be appropriate in 63% of patients only.
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Since its inception in 1999, the role of the National Institute for
Clinical Excellence (NICE) has been to provide patients, healthcare
professionals and the public with guidance on best practice, based
on available evidence. Guidance on specific health technologies,
such as chemotherapy, as well as clinical management of specific
conditions are included in this remit. To date, much has been
written of the potential impact both financially and on clinical
practice of this government ‘watchdog’, but little has been
published on whether or not it has been possible for this guidance
to be successfully implemented within the National Health Service
(NHS). NICE has recommended that ‘paclitaxel in combination
with a platinum therapy (cisplatin or carboplatin) should be the
standard initial therapy for patients with ovarian cancer following
surgery’ (NICE, 2000). The additional cost (outside therapeutic
trials and private prescription) to the NHS of using taxanes in
patients with ovarian cancer is estimated at 7 million pounds (Dent
and Sadler, 2002).
All new cases of ovarian cancer diagnosed in the Grampian
region and confirmed by a single pathology laboratory are entered
into the gynaecological cancer database at Aberdeen Royal
Infirmary. Standard management of ovarian cancer by the
designated gynaecological oncology service, outwith ongoing
clinical trials, is surgical staging where possible followed by six
cycles of first-line combination chemotherapy with carboplatin
(AUC6) and paclitaxel (175mgm
 2).
The aim of this study was to see if NICE guidance on
chemotherapy for ovarian cancer was implementable in our
population. We have therefore performed a prospective popula-
tion-based study to see if adjuvant treatment with carboplatin/
cisplatin and a taxane, paclitaxel/docetaxel is deliverable in every
newly diagnosed case of ovarian cancer.
MATERIALS AND METHODS
All patients with newly diagnosed epithelial ovarian cancer entered
into the gynaecological database from 1 March 1998 to 1 March
2001 were prospectively followed. For each patient a large number
of parameters are entered into the cancer database, but for the
purposes of this study attention was confined to the following: age,
performance status based on Eastern Cooperative Oncology Group
(ECOG), surgical treatment, if any, and adjuvant treatment, that is
chemotherapy/radiotherapy. With regard to chemotherapy, the
type, dose, duration and indications for withholding or disconti-
nuing treatment were noted.
RESULTS
During the 36-month period studied, 133 newly diagnosed cases of
ovarian cancer were entered into the gynaecological cancer
database. A total of 113 patients (85%) had surgical staging. In
all, 15 patients had early disease, stage 1, and therefore adjuvant
chemotherapy was not indicated. One patient had a mixed
Mullerian tumour and a doxorubicin/ifosphamide regime was
more appropriately administered. The remaining 117 patients
identified as requiring chemotherapy had a pathological diagnosis
of epithelial ovarian carcinoma. In all, 34 (29%) of these patients
Table 1 Type of treatment used
Type of treatment N%
Carboplatin/paclitaxel 51 43.6
Carboplatin/docetaxel 17 14.5
Carboplatin only 37 31.6
Chlorambucil 2 1.7
Chemo/radiotherapy 1 0.9
Radiotherapy 2 1.7
No treatment 7 6.0
Total 117
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treatment used. One patient declined treatment on social grounds
and died within 1 week of diagnosis of disease. Six patients died of
disease within 1 month of diagnosis and before treatment could
have been commenced. Disease was confined to the pelvis in two
patients and the option of adjuvant radiotherapy alone was used.
Performance status precluded intravenous chemotherapy in two
patients but both received oral chlorambucil. No patient was
refused treatment for social reasons.
A platinum/taxane combination was used in 68 of the remaining
patients, 64% (N¼106). Docetaxel was administered within the
confines of ongoing trials (dose: 100mgm
 2 within SCOTROC 1
and 100/75/25mgm
 2 within SCOTROC 11). The median age of
this group of patients was 58 years (range, 30–83 years). All but
one patient had had a laparotomy as part of their management
prior to chemotherapy. All but five patients completed six cycles of
combination therapy. Two patients had an allergic reaction to the
first dose of paclitaxel (2.9%); two patients developed symptoms of
neurotoxicity necessitating discontinuing paclitaxel after five
cycles and a rising Ca125 in one patient during docetaxel treatment
within SCOTROC 11 prompted a change to carboplatin treatment
alone. A platinum/taxane combination was not used in the
remaining 38 patients. One patient received carboplatin and pelvic
irradiation and Table 2 lists the reasons why 37 patients received
carboplatin only. The median age of these patients was 76 years
(range, 50–94 years). In all, 14 patients in this group did not have
a laparotomy prior to receiving chemotherapy. All but 13 patients
completed six cycles of treatment in whom the indications for
cessation or a change of treatment were: a rising Ca125, 6; death, 3;
renal impairment, 2; and marrow suppression, 2.
DISCUSSION
The inequality of the ‘postcode’ delivery system of healthcare seen
across the NHS was one of the main reasons why NICE was
conceived. The recommendations of NICE should therefore have a
significant impact on the quality and consistency of care of
patients. The Department of Health expects the recommendations
of NICE to be followed and has emphasised this particularly in
relation to new drugs for cancer. Such dogma in reality, however,
fails to consider other factors such as competing treatments and
the particular needs of patients within a given Health Authority at
any one time. For the patient and relative, to whom the work of
NICE is freely available, NICE may provoke some concern
regarding the receipt of appropriate treatment. However, they
must be reminded that all NICE guidance documents begin with a
caveat that allows clinical judgement to be exercised in any
individual case.
The Grampian supra regional service described here is not
subject to differences in referral practice or postcode prescribing
as might be experienced in other UK regions, particularly where
public/private prescribing may have an impact on ultimate
treatment. The fact that all cases are centrally referred, and
funding for chemotherapy, in particular taxanes, is available
irrespective of recruitment to clinical trials provides an ideal group
for studying the impact of national guidelines.
In the present study, of those patients in whom it was indicated,
all but seven received some form of adjuvant treatment (94%,
N¼117). Overall therefore, age and comorbidity did not preclude
treatment, although these two factors constituted the main reasons
as to why combination therapy to include a taxane was not
recommended in one-third of patients (33%, N¼117). Sundarar-
ajan et al (2002) have previously shown a significant variation in
the use of chemotherapy in the elderly with patients over the age of
65 years not only less likely to receive any form of chemotherapy
but also less likely to receive combination therapy.
Patients with newly diagnosed ovarian cancer represent a
heterogeneous group. We report our experience with adjuvant
chemotherapy in these patients as a guide to the likelihood of
being able to implement the recommendations of NICE for which
there is little published data thus far. In view of the recently
published ICON3 study, which concludes that single-agent
carboplatin or cisplatin are as effective as a paclitaxel/carboplatin
combination in survival terms and with a considerably better
toxicity profile, a review of the evidence on the use of taxanes in
the treatment of ovarian cancer by NICE would be anticipated
(ICON Group, 2002). In the meantime, we conclude that even in
the presence of an aggressive chemotherapy practice, combination
treatment based on present NICE guidance is not deliverable in all
patients with ovarian cancer.
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